JP2004520157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520157A5 JP2004520157A5 JP2002557374A JP2002557374A JP2004520157A5 JP 2004520157 A5 JP2004520157 A5 JP 2004520157A5 JP 2002557374 A JP2002557374 A JP 2002557374A JP 2002557374 A JP2002557374 A JP 2002557374A JP 2004520157 A5 JP2004520157 A5 JP 2004520157A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- particles
- particle
- active
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 18
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000007788 liquid Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 4
- 239000002105 nanoparticle Substances 0.000 claims 3
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 2
- 230000003182 bronchodilatating Effects 0.000 claims 2
- 239000012159 carrier gas Substances 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002360 explosive Substances 0.000 claims 2
- 239000012527 feed solution Substances 0.000 claims 2
- 239000003337 fertilizer Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000049 pigment Substances 0.000 claims 2
- 239000003380 propellant Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229940092705 Beclomethasone Drugs 0.000 claims 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N Bricaril Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- 229960001419 Fenoprofen Drugs 0.000 claims 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 claims 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims 1
- 229940088597 Hormone Drugs 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- 229960000905 Indomethacin Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002288 Procaterol Drugs 0.000 claims 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N Procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- 229960000195 Terbutaline Drugs 0.000 claims 1
- 229940088594 Vitamin Drugs 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 238000005054 agglomeration Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000003905 agrochemical Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 1
- 230000002075 anti-alcohol Effects 0.000 claims 1
- 230000003556 anti-epileptic Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 150000008282 halocarbons Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 230000003344 immunostimulant Effects 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- -1 photochemical Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000002285 radioactive Effects 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 229930003231 vitamins Natural products 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Claims (18)
- 活性剤の、遊離している粒子の空気動力学的粒径が200nm未満である、ナノサイズの粒子の製造方法であって、
1つの活性剤または2つ以上の活性剤の組み合わせを含有する液体供給原料を調製する工程;
該液体供給原料を霧状にして、液滴を製造する工程;
該液滴をキャリアガス中に浮遊させる工程;
該キャリアガスとそこに浮遊させた液滴を、所定の滞留時間および温度経過の下で、加熱した管型流通反応装置に通過させる工程;および
生じたナノサイズの粒子を収集する工程、
を包含する製造方法。 - 前記粒子の空気動力学的粒径が100nm未満である請求項1記載の方法。
- 前記粒子が結晶質であって、かつ制御された粒子サイズおよび粒子形を有する請求項1記載の方法。
- 前記粒子の幾何標準偏差が2未満である粒子サイズ分布を有する請求項1、2または3記載の方法。
- 前記粒子が帯電していない請求項1、2、3または4記載の方法。
- 前記粒子が、静電集塵器、サイクロン、フィルタ、沈殿チャンバおよびインパクタからなる群から選択される粒子収集系を用いて収集される請求項1、2、3、4または5記載の方法。
- 粒子収集系が、前記液体供給原料溶液の凝集を防ぐために液体供給原料溶液の露点をこえる温度に加熱される請求項1、2、3、4、5または6記載の方法。
- 前記液体供給原料が、溶液、懸濁液、分散液、ゲル、エマルジョン、スラリーの形態である請求項1、2、3、4、5、6または7記載の方法。
- 前記溶液の溶媒が、水、炭化水素、ハロゲン化炭化水素、アルコール、ケトンである請求項8記載の方法。
- 前記活性剤が、治療用薬剤、化粧用薬剤または診断用薬剤である請求項1、2、3、4、5、6、7、8または9記載の方法。
- 前記活性剤が、光化学物質、触媒、肥料、色素、推進薬、食物、火薬または農業用薬剤である請求項1、2、3、4、5、6、7、8、9または10記載の方法。
- 前記治療用薬剤が、抗炎症剤、気管支拡張剤、抗生物質、抗ウイルス剤、免疫抑制剤、免疫刺激剤、抗真菌剤、麻酔剤、抗酸化剤、抗糖尿病剤、ビタミン、ホルモン、抗癲癇剤、抗ガン剤、筋肉弛緩剤、抗HIV剤、刺激剤、鎮咳剤、陣痛制御剤、禁煙剤、抗アルコール中毒剤である請求項10記載の方法。
- 前記抗炎症剤が、アスピリン、ナプロキセン、インドメタシン、イブプロフェン、フェノプロフェン、アセトミノフェン、ベクロメタゾン、ジクロフェナクおよびそれらの塩である請求項12記載の方法。
- 前記気管支拡張剤が、サルブタモール、サルメテロール、フォルモテロール、テルブタリン、プロカテロールまたはそれらの塩である請求項12記載の方法。
- 前記活性剤が、ペプチド、タンパク質、ステロイド、核酸、炭水化物、脂質または放射性化合物である請求項10記載の方法。
- 請求項1、2、3、4、5、6、7、8、9、10、11、12、13、14または15記載の方法により製造されたナノサイズの粒子。
- 乾燥粉末、錠剤、カプセル、液体またはコロイド懸濁液中に分散させた粒子として処方される請求項16記載のナノサイズの粒子。
- 請求項16に記載のナノサイズの粒子を含有する薬学的組成物、化粧用組成物、診断用組成物、光化学物質、触媒、肥料、色素、推進薬、食物、火薬または農業用組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20010115A FI20010115A0 (fi) | 2001-01-18 | 2001-01-18 | Menetelmä nanopartikkelien valmistamiseksi |
FI20010115 | 2001-01-18 | ||
PCT/FI2002/000042 WO2002056866A1 (en) | 2001-01-18 | 2002-01-18 | A method for the preparation of nanoparticles |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004520157A JP2004520157A (ja) | 2004-07-08 |
JP2004520157A5 true JP2004520157A5 (ja) | 2007-12-13 |
JP4728558B2 JP4728558B2 (ja) | 2011-07-20 |
Family
ID=8560060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002557374A Expired - Lifetime JP4728558B2 (ja) | 2001-01-18 | 2002-01-18 | ナノ粒子の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040091542A1 (ja) |
EP (1) | EP1351666B1 (ja) |
JP (1) | JP4728558B2 (ja) |
AT (1) | ATE387185T1 (ja) |
DE (1) | DE60225242T2 (ja) |
FI (1) | FI20010115A0 (ja) |
WO (1) | WO2002056866A1 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
EP1625333A1 (en) | 2003-05-21 | 2006-02-15 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
EP1718446A4 (en) * | 2004-02-24 | 2009-12-09 | Luna Innovations Inc | METHOD AND SYSTEMS FOR EFFICIENT PRODUCTION OF POLYMER MICROSPHERES |
US8758821B2 (en) | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
CN1950071A (zh) | 2004-05-04 | 2007-04-18 | 霍尔莫斯医疗有限公司 | ospemifene的新口服制剂 |
US20090028948A1 (en) * | 2004-12-31 | 2009-01-29 | Iceutica Pty Ltd | Nanoparticle composition and methods of synthesis thereof |
JP4979203B2 (ja) * | 2005-05-31 | 2012-07-18 | 栗田工業株式会社 | 吸着構造体およびその製造方法 |
CN101384247B (zh) | 2005-07-18 | 2013-05-22 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
HUE054852T2 (hu) * | 2005-12-01 | 2021-10-28 | Univ Massachusetts Lowell | Botulinum nanoemulziók |
CN1785153B (zh) * | 2005-12-06 | 2010-04-21 | 青岛大学 | 纳米级材料制备装置及纳米抗氧化活性多肽药物的制备方法 |
JP2007301534A (ja) * | 2006-05-15 | 2007-11-22 | Ebara Corp | 微細化装置 |
EP2018875A1 (en) | 2006-05-15 | 2009-01-28 | Ebara Corporation | Poorly-water-soluble pharmaceutical agent |
DE102006026578B4 (de) * | 2006-06-08 | 2009-01-08 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffpartikelhaltiges Transdermales Therapeutisches System mit erhöhtem Wirkstofffluss und Verfahren zu seiner Herstellung sowie Verwendung |
WO2008000042A1 (en) | 2006-06-30 | 2008-01-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
AU2007329579A1 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Amphiphilic entity nanoparticles |
CN107080703A (zh) | 2006-12-01 | 2017-08-22 | 安特里奥公司 | 肽纳米粒子和其用途 |
CA2672261C (en) * | 2006-12-11 | 2014-09-23 | Drugrecure Aps | Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin |
ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
EP2162117B1 (en) | 2007-05-31 | 2018-02-21 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
US20110182994A1 (en) * | 2008-07-25 | 2011-07-28 | S.K. Pharmaceuticals, Inc. | Methods and systems for production of nanoparticles |
NZ595986A (en) | 2009-04-24 | 2014-04-30 | Iceutica Pty Ltd | A novel formulation of indomethacin |
DE102014011635A1 (de) | 2013-09-04 | 2015-03-05 | Chemiewerk Bad Köstritz GmbH | Verfahren zur Herstellung von nanostrukturierbaren Mikropartikeln aus fluiden Medien mittels Sprühtrocknung |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
JP2019535829A (ja) | 2016-11-21 | 2019-12-12 | エイリオン セラピューティクス, インコーポレイテッド | 大型薬剤の経皮送達 |
CN110232214B (zh) * | 2019-05-09 | 2020-07-28 | 北京大学 | 一种通过数值模拟的食品预冷性能评估和优化方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
GB9105705D0 (en) * | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5819726A (en) * | 1993-01-29 | 1998-10-13 | Aradigm Corporation | Method for the delivery of aerosolized drugs to the lung for the treatment of respiratory disease |
US5833892A (en) * | 1996-07-12 | 1998-11-10 | Kemira Pigments, Inc. | Formation of TiO2 pigment by spray calcination |
US6338809B1 (en) * | 1997-02-24 | 2002-01-15 | Superior Micropowders Llc | Aerosol method and apparatus, particulate products, and electronic devices made therefrom |
US6051257A (en) * | 1997-02-24 | 2000-04-18 | Superior Micropowders, Llc | Powder batch of pharmaceutically-active particles and methods for making same |
-
2001
- 2001-01-18 FI FI20010115A patent/FI20010115A0/fi unknown
-
2002
- 2002-01-18 EP EP02710900A patent/EP1351666B1/en not_active Expired - Lifetime
- 2002-01-18 WO PCT/FI2002/000042 patent/WO2002056866A1/en active IP Right Grant
- 2002-01-18 US US10/466,365 patent/US20040091542A1/en not_active Abandoned
- 2002-01-18 DE DE60225242T patent/DE60225242T2/de not_active Expired - Lifetime
- 2002-01-18 JP JP2002557374A patent/JP4728558B2/ja not_active Expired - Lifetime
- 2002-01-18 AT AT02710900T patent/ATE387185T1/de not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004520157A5 (ja) | ||
DE60225242T2 (de) | Verfahren zur herstellung von nanopartikeln | |
DE60107862T2 (de) | Inhalationspartikel bestehend aus mindestens zwei wirkstoffen | |
CN102883798B (zh) | 用于制备微粒和纳米粒的方法和设备 | |
KR100348935B1 (ko) | 활성성분의조절된방출을갖는고체형태제조용장치및방법 | |
JP3100626B2 (ja) | エアロゾルキャリヤー | |
DE60127407T2 (de) | Hochwirksame verabreichung eines aerosols mit hoher therapeutischer masse | |
JP4768212B2 (ja) | 喘息治療のための組合せ粒子 | |
IE53640B1 (en) | Inhalation pharmaceuticals | |
HRP20050546A2 (en) | Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation | |
JPH07504432A (ja) | 医薬製剤 | |
Chandra Nandy et al. | Formulation and characterizations of delayed release multi-particulates system of indomethacin: optimization by response surface methodology | |
Hadiwinoto et al. | Integrated continuous plug-flow crystallization and spray drying of pharmaceuticals for dry powder inhalation | |
WO2003077886A1 (fr) | Procede de fabrication de particules composites contenant un produit chimique | |
Saboti et al. | Novel budesonide particles for dry powder inhalation prepared using a microfluidic reactor coupled with ultrasonic spray freeze drying | |
DE60023547T2 (de) | Partikel zur inhalation | |
Rao et al. | Formulation and in-vitro evaluation of indomethacin microcapsules | |
Raula et al. | Aerosol flow reactor method for the synthesis of multicomponent drug nano-and microparticles | |
GB2232891A (en) | Pharmaceutical nedocromil composition for inhalation | |
Patil et al. | Utilization of Natural Olibanum Gum Resin as a Rate Controlling Polymer in Design and Evaluation of Microspheres of an Antiretroviral Drug by using a Unique Spray Drying Technique | |
DE3903217A1 (de) | Verfahren zur herstellung fester pharmazeutischer zubereitungen | |
CN1816322B (zh) | 颗粒材料 | |
Rastogi et al. | Formulation development and evaluation of Aceclofenac Chitosan Microspheres |